Evidence for a High Affinity, Saturable, Prenylation-dependent p21Ha-ras Binding Site in Plasma Membranes*

Afzal A. Siddiqui, John R. Garland, Marguerite B. Dalton, and Michael SinenskyDagger

From the Department of Biochemistry and Molecular Biology East Tennessee State University, James H. Quillen College of Medicine, Box 70581, Johnson City, Tennessee 37614-0581

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Oncogenic p21ras proteins can only exert their stimulation of cellular proliferation when plasma membrane-associated. This membrane association has an absolute requirement for post-translational modification with isoprenoids. The mechanism by which isoprenoids participate in the specific association of p21ras with plasma membranes is the subject of this report. We present in vitro evidence for a plasma membrane binding protein for p21ras that can recognize the isoprenoid substituent and, therefore, may facilitate the localization of p21ras.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Post-translational modification with isoprenoids results in considerable structural diversity at the carboxyl terminus of many proteins. Four such carboxyl-terminal structural motifs have been identified (for review see Ref. 1). These are farnesylated-methylated cysteine, geranylgeranylated-methylated cysteine, digeranylgeranylated vicinal cysteines of the -CC rab proteins, and digeranylgeranylated residue-interrupted cysteines of the -CXC rab proteins. The carboxyl-terminal cysteine of the -CXC rabs is methylated, whereas the carboxyl-terminal cysteine of the -CC rabs is not. Since these modifications always increase the hydrophobic character of the substituted proteins, it is generally assumed that they are involved in the association of proteins so modified with lipid bilayer membranes. This assumption is supported by the observation that most prenylated proteins are bound to cellular membranes, at least under some physiological conditions.

A more recent hypothesis for the function of protein prenylation that is more in keeping with the observed structural diversity and membrane specificity is that these lipid modifications also serve to mediate protein-protein interactions (2). A well studied example of this function for protein prenylation is the heterodimeric association of rab proteins with GDP dissociation inhibitor molecules to form soluble complexes that appear to be dependent on the digeranylgeranylation of the rab proteins (3). Another recent example from our laboratory is the mechanism of endoproteolytic cleavage of the farnesylated prelamin A molecule, which is mediated by an enzyme that possesses a specific farnesyl binding site (4).

It has been noted that it is possible that even membrane-associated prenylated proteins may utilize a polyisoprenoid-dependent protein-protein interaction for membrane binding (2). Recognition of the polyisoprenoid and other structural elements of the protein by membrane receptors could confer the necessary localization of particular prenylated proteins to particular subcellular compartments. Sequestration of the polyisoprenoid would be important in preventing nonspecific association of the protein with inappropriate membranes.

Farnesylated proteins are found in a number of cellular compartments (1) including plasma membrane (p21ras, gamma -transducin), peroxisomes (PxF) and nuclei (lamin B, prelamin A). For the naturally occurring forms of N, H, and K p21ras, it is clear that plasma membrane localization shows an absolute requirement for farnesylation (5), yet the occurrence of farnesylated proteins in other compartments suggests the existence of some high affinity plasma membrane receptor that can recognize not only the isoprenoid but other structural features of the protein as well. Studies on site-directed mutagenic alterations of p21ras proteins are consistent with this concept and have clearly identified the hypervariable region of p21ras as a second domain that specifies its plasma membrane localization (6). In this report we present quantitative in vitro binding studies that confirm the existence of a high affinity plasma membrane receptor for p21ras.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

NIH3T3 Mouse Fibroblast Culture and Plasma Membrane Isolation-- NIH3T3 mouse fibroblast cultures were grown in Dulbecco's modified Eagle's medium (high glucose) (Nova-Tech, Inc.) supplemented with 10% fetal bovine serum (v/v) (Life Technologies, Inc.), 100 units/ml penicillin, 100 µg/ml streptomycin, and 1 µg/ml amphotericin B. Twenty-four h before harvesting the cells for plasma membrane isolation, culture media was supplemented with 8 µg/ml lovastatin to deplete the association of endogenous p21ras with the plasma membrane.

A highly enriched plasma membrane fraction from NIH3T3 cells was isolated as described (7). A protease inhibitor mix (1 mM each of antipain, aprotinin, bestatin, chymostatin, pepstatin A, leupeptin, and phenylmethylsulfonyl fluoride) was added to the plasma membrane fractions that were stored at -70 °C until used. The purity of plasma membrane fraction was assessed via marker enzyme activities of 5'-nucleotidase (8) and glucose 6-phosphatase (9).

Generation of Recombinant Baculovirus-expressing His-tagged H, N, and K p21ras, CVLL-p21Ha-ras and Lamin B; Purification of Recombinant Proteins and Iodination of p21Ha-ras-- Recombinant baculovirus-expressing p21Ha-ras with a histidine tag affixed to its N terminus was a gift from Dr. Sandra L. Hoffmann (University of Texas Southwestern Medical Center, Dallas, TX). A BamHI/SalI fragment containing full-length coding sequence of p21Ki-ras4B and a BamHI/HindIII fragment containing full-length sequence of p21N-raswere cloned into compatible cloning sites of pBlueBacHis2 vector (Invitrogen, San Diego, CA). The constructs were cotransfected with Bac-N-Blue baculovirus DNA into sf-9 cells (Invitrogen) with the aid of a cationic liposome-mediated transfection kit (Invitrogen) employed according to the manufacturer's instructions. The recombinant baculoviruses were screened for and isolated in sf-9 cells as described (10). A single virus clone for each of the proteins was chosen for all further experimentation. Approximately, 5 × 106 sf-9 cells (Invitrogen)/75-cm2 flask were infected (~1 plaque-forming unit/cell) with recombinant baculoviruses derived from p21Ha-ras, p21Ki-ras, and p21N-ras constructs, respectively. The infected cells were grown in complete TNM-FH media (Invitrogen) supplemented with 10 µg/ml gentamicin at 27 °C for 48 h. The infected sf-9 cells were collected by centrifugation and after several washings with PBS,1 were processed for membrane and cytoplasmic fractions isolation (11, 12). Both cytoplasmic- and membrane-associated forms of recombinant p21Ha-ras and membrane-associated forms of p21Ki-ras and p21N-ras were purified via metal affinity chromatography Xpress System (Invitrogen) and imidazole elution (50-75 mM). Recombinant baculovirus-expressing CVLL-p21Ha-ras was a gift from (Dr. Paul Kirschmeier, Schering-Plow Research Institute, Kenilworth, NJ). sf-9 cells were infected with recombinant baculovirus-expressing CVLL-p21Ha-ras as above, and the resultant protein was purified as described (10). A highly purified preparation of lamin B was obtained from rat liver using published procedures (13).

Recombinant p21Ha-ras derived from the membrane fraction of infected sf-9 cells was tagged with 125I (NEN Life Science Products/Dupont) in the presence of Iodo-Beads (Pierce) according to the manufacturer's instructions. Unbound 125I was removed via dialysis.

Binding of 125I-labeled p21Ha-ras to NIH3T3 Plasma Membranes and Competition Assays-- Aliquots of plasma membranes (100 µg of protein) were incubated with varying concentrations of 125I-p21Ha-ras (5-150 nM) with or without a 100-fold excess of unlabeled p21Ha-ras in a total volume of 100 µl. The incubation medium consisted of phosphate-buffered saline containing 5 mM MgCl2, 30 µM guanosine 5'-diphosphate, 0.1% bovine serum albumin, 0.5 M NaCl, and 0.8% Triton X-100. The binding of the radioactive ligand was allowed to proceed for 1 h at 25 °C. Incubations were terminated by the addition of ice-cold PBS containing 0.8% Triton X-100 and 0.1% bovine serum albumin. The unbound radioactivity was removed via filtration of the reaction mixture through Whatman glass microfiber filters. The filters were washed >6 times with PBS containing 0.8% Triton X-100 and 0.1% bovine serum albumin and air-dried, and radioactivity was counted in a gamma counter.

A time course experiment for binding was performed for 15, 30, 45, 60, and 75 min, utilizing the optimal conditions outlined above. Saturation of the binding was observed after 45 min, and therefore all experiments were conducted for 1 h. To determine reversibility of binding, matched samples of plasma membranes (100 µg of protein) were incubated with 125I-p21Ha-ras (125 nM), and the binding of the radioactive ligand was allowed to proceed at 25 °C. After a 1-h incubation, a 100-fold excess of unlabeled p21Ha-ras was added to one set of samples, and incubation was continued for an additional 1 h. Incubations were then terminated by the addition of ice-cold PBS containing 0.8% Triton X-100 and 0.1% bovine serum albumin. The reaction mixture was then centrifuged at 13,000 × g for 15 min, and the difference between the membrane-bound counts in the presence and absence of excess unlabeled p21Ha-ras was determined.

To study the effect of different competitors (non-farnesylated p21Ha-ras, bovine serum albumin, p21N-ras p21Ki-ras, CVLL-p21Ha-ras, rat liver lamin B, LLGNSSPRTQSPQNCfarnesyl, and N-acetyl farnesyl methyl cysteine) on binding of iodinated p21Ha-ras to plasma membranes, varying concentrations (5 nM to 5 µM) of competitors were added with 125I-p21Ha-ras (50 nM) under binding conditions outlined above.

Nonlinear regression analysis of saturation binding and competitive inhibition data were performed with SigmaPlot (Jandel Scientific, San Rafael, CA). Scatchard plot analysis and calculations of IC50 values were performed as described (14) with the linear regression performed with Sigma Plot.

To evaluate whether the binding of p21Ha-ras to plasma membrane is dependent on p21Ha-ras being bound to GTP or GDP, the binding studies were carried out in the presence of 30 µM GDP or 25 µM GTPgamma S (Biomol) under the conditions outlined for binding of 125I-labeled p21Ha-ras to NIH3T3 plasma membranes above. These concentrations of unbound ligand are approximately 1,000-fold excess to the concentration of GDP-loaded p21Ha-ras, which gives half-maximal binding to plasma membranes. Binding reaction mixes were preincubated at 37 °C for 100 min in the absence of membranes to allow nucleotide exchange to occur (15) and transferred to a 25 °C water bath, and the binding reaction was initiated by the addition of membranes.

Ligand Blotting Assays-- Ligand blots were performed by a previously described method (16) with some modifications. Approximately 25 µg of NIH3T3 plasma membrane proteins were separated via SDS-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. The blots were incubated in PBS containing 0.3% Tween, 0.5% Triton X-100, 5 mM MgCl2, 30 µM guanosine 5'-diphosphate, 0.1% bovine serum albumin, and 125I-p21Ha-ras (50 nM) with or without a 100-fold excess of unlabeled p21Ha-ras with constant shaking at 25 °C. After an 18-h incubation, blots were washed (>5 times) with PBS containing 0.3% Tween and 0.5% Triton X-100, air-dried, and exposed to Kodak X-Omat AR film at -70 °C.

Binding of Iodinated p21Ha-ras with Trypsin-treated Plasma Membranes-- To determine if the binding of iodinated p21Ha-ras is to the protein component(s) of the plasma membrane, NIH3T3 plasma membranes were pretreated with trypsin (10 µg/ml) for 30 min at 25 °C followed by the addition of protease inhibitor mix. For control experiments, trypsin was inactivated with protease inhibitor mix and then added to the binding reaction mixture. For other series of experiments, plasma membrane proteins were also inactivated by incubation at 100 °C for 5 min. The binding studies were carried out exactly as above.

Other Assays-- Protein concentrations were determined by BCA method (Pierce). N-Acetyl farnesyl methyl cysteine was prepared by acid-catalyzed methylation of commercial N-acetyl farnesyl cysteine (Calbiochem) as described previously (17). Gas-liquid chromatographic analysis of the radiolabeled isoprenoid group of baculovirus-generated p21Ha-ras was done after Raney nickel cleavage of immunoprecipitated [3H]mevalonate-labeled protein, as described previously (18).

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Saturation Binding of Farnesylated p21Ha-ras to 3T3 Cell Plasma Membranes-- Farnesylated, geranylgeranylated, and nonprenylated p21Ha-ras proteins were synthesized in the baculovirus insect cell expression system, and the proteins were purified to homogeneity as described under "Materials and Methods" (Fig. 1). All of the baculovirus-generated p21Ha-ras proteins showed immunoreactivity with Y13-259 antibody in Western blots (data not shown). Synthesis of protein in the presence of [3H]mevalonate followed by immunoprecipitation gave rise to labeled material from membranes. This material was analyzed for farnesylation by Raney nickel cleavage followed by radiolabeled gas-liquid chromatography and radiodetection (Fig. 2) as described previously (18). These results further demonstrate that we have prepared bona-fide p21Ha-ras in sf-9 insect cells, as has also been reported elsewhere (11, 19-21).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   SDS-polyacrylamide gel electrophoresis analysis of the baculovirus-generated p21ras proteins. A Coomassie-stained 10% polyacrylamide minigel with membrane-associated p21Ha-ras (lane 1), cytosolic p21Ha-ras (lane 2), CVLL-p21Ha-ras (lane 3), p21Ki-ras (lane 4), p21N-ras (lane 5), and lamin B from rat liver (lane 6) is shown.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Farnesylation of membrane-associated p21Ha-ras expressed in sf-9 cells. Infected cells were incubated at room temperature overnight with [3H]mevalonolactone (200 µCi/ml) in the presence of 25 µM lovastatin. Labeled p21Ha-ras derived from the membrane fraction of infected sf-9 cells was treated with Raney nickel to release the isoprenoid moiety, which was then analyzed by gas-liquid chromatography and radiodetection (B). The peaks for p21Ha-ras were identified by comparison of retention time values with the ones generated from Raney nickel-treated synthetic farnesyl (peak 1) and geranylgeranyl cysteine methyl esters (peak 2) (A). Recombinant p21Ha-ras released only the farnesyl group (A, peak 1). FID, flame ionization detector; cps, counts/s; stds, standards.

NIH3T3 cells were pretreated with lovastatin for 24 h before harvest for membrane preparation to decrease any endogenous p21ras occupancy of potential farnesylation-dependent binding sites. An enriched plasma membrane fraction from lovastatin-treated NIH3T3 cells was prepared by means of discontinuous Ficoll and sucrose density gradients. Marker enzyme analysis of the plasma membrane fraction showed that the specific activity of 5'-nucleotidase was 12.5-fold enriched in this fraction compared with the initial homogenate. Based on glucose-6-phosphatase activity, the cross-contamination of the plasma membrane fraction with microsomes was approximately 11%.

We examined the kinetics of binding of the purified, 125I-p21Ha-ras to the NIH3T3 plasma membranes, subtracting out nonspecific binding estimated from the binding in the presence of excess unlabeled ligand. The results (Fig. 3) are consistent with a saturable binding site for p21Ha-ras, presumably a receptor protein. At saturation, approximately 53% of the total binding was specific binding of 125I-p21Ha-ras to the NIH3T3 plasma membranes. Scatchard analysis of the specific ligand binding data (Fig. 3, inset) using a one-site model yielded an estimated Kd and Bmax values of 24.4 ± 5.3 nM (mean ± S.D.) and 137.3 ± 27.1 pmol/mg of protein, respectively. To determine if the binding is reversible under these conditions, 125I-p21Ha-ras was allowed to bind with plasma membranes to saturation, and then a 100-fold excess of unlabeled p21Ha-ras was added to the assay mixture. After 1 h, nearly half of the counts had been displaced from the membranes, consistent with reversible association of the ligand with the binding site.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Saturation binding of 125I-p21Ha-ras (farnesylated) to NIH3T3 plasma membranes and Scatchard plot (one-site model) of specific binding showing estimates of Kd and Bmax. Aliquots of plasma membranes were incubated with varying concentrations of 125I-p21Ha-ras (5-150 nM) with or without a 100-fold excess of unlabeled p21Ha-ras as described under "Materials and Methods." Every data point represents an average (±S.D.) of five replicates of three independent experiments (n = 15).

We also examined the effect of the GTP loading on the membrane binding. To do this, binding was assayed with p21Ha-ras loaded with GTPgamma S, a nonhydrolyzable GTP analogue. The GTPgamma S-loaded p21Ha-ras binding exhibited negative cooperativity, with an n value of 0.0342 (Fig. 4).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 4.   Binding of 125I-p21Ha-ras loaded with the GTP analogue GTPgamma S to NIH3T3 plasma membranes. A Hill plot analysis of the binding data is also shown. Aliquots of plasma membranes were incubated with varying concentrations of 125I-p21Ha-ras (5-150 nM) with or without a 100-fold excess of unlabeled p21Ha-ras in the presence of 30 µM GDP or 25 µM GTPgamma S as described under "Materials and Methods." Every data point represents an average (±S.D.) of three replicates of two independent experiments (n = 6). Y, fractional saturation.

To verify the protein nature of this putative receptor, we examined the effect of treatment of the plasma membranes with heat or trypsin on the binding activity. Treatment of plasma membranes with either heat or trypsin significantly decreased 125I-p21Ha-ras binding (Fig. 5). These results clearly demonstrate that the preferential association of p21Ha-ras with plasma membranes is due to a nonlipid component, i.e. a protein. Comparison of binding activities of the different membrane fractions from the gradient also confirmed that the putative receptor for p21Ha-ras co-purified with the plasma membrane-enriched fraction (Fig. 5).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 5.   Binding of 125I-p21Ha-ras (farnesylated) to different subcellular fractions of NIH3T3 cells. NIH3T3 plasma membrane and microsomal and large particulate fractions were assayed for p21Ha-ras binding activity with 50 nM p21Ha-ras. In one set of experiments, the fractions were pretreated with trypsin or trypsin inactivated with protease inhibitor mix. In another series of experiments, subcellular fractions were also inactivated by incubation at 100 °C for 5 min. The binding studies were carried out as described under "Materials and Methods." The mean and S.D. of three determinations from two independent experiments are shown.

Role of the Farnesyl Group in Receptor Binding-- The saturation binding assay described above provides a method for quantitatively determining the effect of the farnesyl group on binding of p21Ha-ras to its receptor in plasma membranes. We performed competitive inhibition studies with baculovirus-generated nonfarnesylated cytosolic p21Ha-ras. The cytosolic protein has been shown to be concentrated in the aqueous layer after Triton X-114 partitioning and, hence, to be nonlipidated. We confirmed this for our preparations of the cytosolic protein by demonstrating that this material could be farnesylated by reticulocyte lysates in vitro (data not shown). We could not obtain any inhibition of farnesylated p21Ha-ras by the nonfarnesylated protein at concentrations as much as 1,000-fold higher than the farnesylated ligand (Fig. 6). On the other hand, unlabeled, fully processed N, H, or K p21ras prepared from sf-9 cells were all efficient competitive inhibitors.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 6.   Binding of 125I-p21Ha-ras with NIH3T3 plasma membranes in the presence of unlabeled competitors. Nonfarnesylated p21Ha-ras, bovine serum albumin, p21N-ras, p21Ki-ras, CVLL-p21Ha-ras, rat liver lamin B, LLGNSSPRTQSPQNCfarnesyl, and N-acetyl farnesyl methyl cysteine (5 nM to 5 µM) were added with 125I-p21Ha-ras (50 nM) under binding conditions outlined under "Materials and Methods." Calculations of IC50 and Ki values were performed as described (11). BSA, bovine serum albumin.

The farnesylation requirement for receptor binding is indicative of recognition of the polyisoprenoid group. To examine this point further, we synthesized N-acetyl-S-farnesyl methyl cysteine, an analogue of the carboxyl-terminal amino acid residue of the p21ras proteins. This compound is a weak competitive inhibitor of p21Ha-ras binding to the receptor (Table I). Competitive inhibition was also observed with another farnesylated protein, lamin B, and with an S-farnesyl cysteine methyl ester peptide corresponding to the carboxyl-terminal 15 amino acid residues of prelamin A (Table I). These results indicate that although the receptor recognizes the polyisoprenoid moiety, binding is also mediated by another domain on the p21ras protein.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Competitive inhibition of p21Ha-ras binding to plasma membranes

It has been reported that transfection of 3T3 cells with geranylgeranylated p21Ha-ras (CAAX = CVLL) results in a membrane-associated protein that is transforming when oncogenic but inhibits cellular growth p21Ha-ras when wild type (22). We considered the possibility that this observation might reflect some difference in the interaction of this reported (22) geranylgeranylated protein and the wild-type farnesylated protein with the receptor. Competitive inhibition studies with this CVLL mutant of p21Ha-ras, previously shown to be geranylgeranylated and to produce growth inhibition, were performed. The results (Fig. 6) indicate that the, presumably, geranylgeranylated p21Ha-ras has an affinity for the receptor that is comparable to that of the wild-type p21ras proteins. These results suggest that the p21ras receptor does not exhibit a strong discrimination between farnesyl and geranylgeranyl substituents.

Ligand Blot Analysis of p21Ha-ras Binding Sites in the Plasma Membrane-enriched Fraction-- Another technique that can visualize a membrane-associated receptor is ligand blotting (16). In this technique, association of a radioiodinated ligand with its receptor can be demonstrated by SDS-polyacrylamide gel electrophoresis separation of the membrane proteins, their transfer to nitrocellulose filters, and incubation of the filters with ligand. We applied this method to the p21Ha-ras receptor. The results (Fig. 7) indicate two bands that appear to be specifically labeled by 125I-p21Ha-ras at 45 and 35 kDa (lane 1); this binding was almost completely eliminated in the presence of a 100-fold excess of noniodinated farnesylated p21Ha-ras (lane 2). The binding of 125I-p21Ha-ras with 45 and 35 kDa polypeptides in ligand blots was not affected in the presence of a 100-fold excess of nonfarnesylated cytosolic p21Ha-ras (Fig. 7, lane 3). Binding also was seen to be reduced by doing the blots in the presence of 5 µM N-acetyl farnesyl methyl cysteine (Fig. 7, lane 4). These results for the proteins visualized by ligand blot are consistent with the quantitative competitive inhibition of binding seen in Table I. The binding proteins (45 and 35 kDa) almost exclusively partitioned into the detergent phase with Triton X-114 (data not shown), which is consistent with their being intrinsic membrane proteins.


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 7.   Ligand blot analysis of 125I-p21Ha-ras binding sites in NIH3T3 plasma membranes. NIH3T3 plasma membrane proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. The blots were incubated with 125I-p21Ha-ras (50 nM) alone (lane 1) or in the presence of 5 µM unlabeled farnesylated p21Ha-ras (lane 2), 5 µM nonfarnesylated cytosolic p21Ha-ras (lane 3), and 5 µM N-acetyl farnesyl methyl cysteine (lane 4). Proteins capable of binding p21Ha-ras were visualized by autoradiography. The autoradiograms were processed as described under "Materials and Methods."

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Plasma membrane localization of p21ras has been shown to be critical for both normal and oncogenic signaling activities of these proteins (23). Elegant mutant expression studies on recombinant p21ras have demonstrated the structural requirements for N, H, and K p21ras protein localization to cell plasma membranes (5, 24). Plasma membrane association of p21Ha-ras or p21N-ras requires post-translational modification of the protein by two alkyl groups (24). The expression studies indicate that post-translational modification by acylation (palmitoylation at Cys-181 or Cys-185 or N-terminal myristoylation) and/or prenylation (farnesylation or geranylgeranylation) produces at least some association of the dialkylated protein with plasma membranes. Mutants of p21Ha-ras that only undergo farnesylation do not exhibit plasma membrane association of p21ras as detected by immunofluorescence. The carboxyl terminus of p21Ha-ras thus possesses a dialkyl structure that appears to be required for its plasma membrane binding. It has been noted (24) that the close proximity of the N terminus and C terminus of p21ras would cause myristoylated and carboxyl-terminal-monolipidated p21ras to present a structure comparable to that of the wild-type protein. The recognition site for this structure in the plasma membrane has been hypothesized to be a receptor or docking protein that mediates assembly of p21ras into the membrane where it is stabilized by nonspecific lipid-lipid interactions.

The studies reported here, confirm and extend these ideas. Based on the amount of protein per cell (~1 mg/107 cells) and the fraction of total cellular protein found in the plasma membrane-enriched fraction (~5%) used in our binding studies, we estimate that there are approximately 5 × 105 p21ras receptors/cell. This can be compared with the ~5 × 105 sites/cell reported for transmembrane-bridging mitogenic peptide receptors such as those for platelet-derived growth factor and epidermal growth factor (25), which are believed to transduce growth signals through p21ras. If nothing else, this number suggests that the total number of such receptors is relatively small and, therefore, inconsistent with being a lipid or a ubiquitous membrane protein. The Kd (25 nM) we observe for p21Ha-ras binding can be compared with that seen for another farnesylation-dependent protein-protein interaction of p21ras. In vitro binding of p21Ki-ras(4B) to human SOS1 has been shown to be absolutely dependent on farnesylation and exhibits 50% saturation at 200 nM (26). In this comparison, the farnesylation-dependent binding we have observed appears to be at relatively high affinity.

The ligand blot data we report are also consistent with a farnesyl group-dependent binding site for p21ras in plasma membranes. Other p21ras binding activities, with the exception of the cytosolic hSOS1 protein noted above, do not exhibit such a requirement for farnesylation. For example, it has been reported (27) that the 21-24-kDa protein caveolin has p21Ha-ras binding activity. Caveolin was shown not to have an absolute requirement for farnesylation of p21Ha-ras to bind it, whereas our binding activity does. We also tested our ligand blots with parallel immunoblots with anti-caveolin and did not find co-migration of caveolin with p21Ha-ras binding activity (data not shown).

We have recently reported a kinetic analysis (4) of the prelamin A endoprotease that demonstrates that this enzyme functions through specific binding of the farnesyl group of prelamin A as well as another domain on that protein. The studies reported here are consistent with an analogous p21ras receptor that recognizes the lipid moiety but, based on the weak competition for binding of N-acetyl farnesyl cysteine methyl ester (which is also detectable in the ligand blots) and the prelamin A peptide, recognizes other structural features of p21ras as well.

A plasma membrane receptor for p21ras that recognizes the protein at least in part through its isoprenoid substituent is, as noted above, consistent with a large body of literature regarding the effect of site-directed mutations on p21ras localization to the plasma membrane. There are, however, at least two functional interpretations of such a binding protein. Hancock and co-workers (24), have suggested that H and N p21ras assemble into plasma membranes through initial recognition of two alkyl groups by a docking protein. The bound protein is then unloaded into the membrane bilayer where it is stabilized by hydrophobic interaction of the alkyl groups with the lipid bilayer. The binding activity we have identified is certainly consistent with this hypothesis. A second possibility is that the p21ras receptor represents a terminal destination for p21ras. It should be noted in this regard that the Kd for the p21ras receptor is much lower than that reported (28) for binding of the alkylated carboxymethylated model p21Ki-ras4B peptide (Kd = 480 nM) to lipid vesicles, and therefore p21ras receptors could be occupied even though surrounded by lipid bilayer. It is also possible that both the p21ras receptor and the lipid bilayer are terminal destinations for p21ras but mediate different functions.

The reversibility of binding of the farnesylated p21Ha-ras as well as the negatively cooperative binding kinetics observed with GDP and GTPgamma S-loaded p21Ha-ras is consistent with the possibility that the association of p21Ha-ras with the plasma membrane may be regulated. The sigmoidal kinetics observed when the p21Ha-ras is GTP-loaded suggests that the receptor may exist as a homodimer in the membrane. In this regard, it is of interest to note that a pool of farnesylated cytosolic p21ras has been reported to exist in 3T3-L1 cells (29).

    ACKNOWLEDGEMENTS

We thank Drs. Paul Kirschmeier and Adrienne Cox for helpful advice and constructive criticism. We also thank Robin Burdine for excellent technical assistance. We also thank Dr. Fusun Kilic for the synthesis of N-acetyl farnesyl methyl cysteine and for the farnesylation of prelamin A peptide.

    FOOTNOTES

* This research was supported by American Cancer Society Grant BE-21.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 423-439-8367; Fax: 423-439-8235; E-mail: sinensky{at}etsu-tn.edu.

1 The abbreviations used are: PBS, phosphate-buffered saline; GTPgamma S, guanosine 5'-O-(3-thiotriphosphate).

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Zhang, F. L., and Casey, P. J. (1996) Annu. Rev. Biochem. 65, 251-269
  2. Marshall, C. J. (1993) Science 259, 1865-1866[Medline] [Order article via Infotrieve]
  3. Regazzi, R., Kikuchi, A., Takai, Y., and Wollheim, C. B. (1992) J. Biol. Chem. 267, 17512-17519[Abstract/Free Full Text]
  4. Kilic, F., Dalton, M. B., Burrell, S. K., Mayer, J. P., Patterson, S. D., Sinensky, M. (1997) J. Biol. Chem. 272, 5298-5305[Abstract/Free Full Text]
  5. Hancock, J. F., Magee, A. I., Childs, J. E., Marshall, C. J. (1989) Cell 57, 1167-1177[Medline] [Order article via Infotrieve]
  6. Hancock, J. F., Paterson, H., and Marshall, C. J. (1990) Cell 63, 133-139[Medline] [Order article via Infotrieve]
  7. Whittenberger, B., and Glaser, L. (1977) Proc. Natl. Acad. Sci. U. S. A. 75, 2251-2255
  8. Siddiqui, A. A., and Nizami, W. A. (1985) J. Helminthol. 59, 263-266[Medline] [Order article via Infotrieve]
  9. Fleischer, S., and Kervina, M. (1975) Methods Enzymol. 3, 299-311
  10. Summers, M. D., and Smith, G. E. (1987) A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, The Texas Agricultural Experiment Station, College Station, TX
  11. Page, M. J., Hall, A., Rhodes, S., Skinner, R. H., Murphy, V., Sydenham, M., Lowe, P. N. (1989) J. Biol. Chem. 264, 19147-19154[Abstract/Free Full Text]
  12. Camp, L. A., and Hoffman, S. L. (1993) J. Biol. Chem. 268, 22566-22574[Abstract/Free Full Text]
  13. Georgatos, S. D., and Blobel, G. (1987) J. Cell. Biol. 105, 117-125[Abstract]
  14. Bylund, D. B., and Yamamura, H. I. (1990) in Methods in Neurotransmitter Receptor Analysis (Yamamura, H. I., Enna, S. J., and Kuhar, M. J., eds), pp. 1-35, Raven Press, Ltd., New York
  15. Herrmann, C., Martin, G. A., and Wittinghofer, A. (1995) J. Biol. Chem. 270, 2901-2905[Abstract/Free Full Text]
  16. Hossenlopp, P., Seurin, D., Segovia-Quinson, B., Hardouin, S., and Binoux, M. (1986) Anal. Biochem. 155, 138-153
  17. Tan, E. W., Perez-Sala, D., Canada, F., and Rando, R. R. (1991) J. Biol. Chem. 266, 10719-10722[Abstract/Free Full Text]
  18. Khosravi-Far, R., Clark, G. J., Abe, K., Cox, A. D., McLain, T., Lutz, R. J., Sinensky, M., Der, C. J. (1992) J. Biol. Chem. 267, 24363-24368[Abstract/Free Full Text]
  19. Lowe, P. N., Sydenham, M., and Page, M. J. (1990) Oncogene 5, 1055-1058[Medline] [Order article via Infotrieve]
  20. Khosravi-Far, R., and Der, C. J. (1995) Methods Enzymol. 255, 56-60
  21. Porfiri, E., Evans, T., Bollag, G., Clark, R., and Hancock, J. F. (1995) Methods Enzymol. 255, 13-21[Medline] [Order article via Infotrieve]
  22. Cox, A. D., Hisaka, M. M., Buss, J. E., Der, C. J. (1992) Mol. Cell. Biol. 12, 2605-2615
  23. Lowy, D. R., and Williamson, B. M. (1993) Ann. Rev. Biochem. 62, 851-891[CrossRef][Medline] [Order article via Infotrieve]
  24. Cadwallader, K. A., Paterson, H., Macdonald, S. G., Hancock, J. F. (1994) Mol. Cell. Biol. 14, 4722-4730[Abstract]
  25. Pfenning, M. A., and Richelson, E. (1990) in Methods in Neurotransmitter Receptor Analysis (Yamamura, H. I., Enna, S. J., and Kuhar, M. J., eds), p. 156, Raven Press, Ltd., New York
  26. Porfiri, E., Evans, T., Chardin, P., and Hancock, J. F. (1995) J. Biol. Chem. 269, 22672-22677[Abstract/Free Full Text]
  27. Song, K. S., Li, S., Okamato, T., Quilliam, L. A., Sargiacomo, M., Lisanti, M. P. (1996) J. Biol. Chem. 271, 9690-9697[Abstract/Free Full Text]
  28. Ghomaschi, F., Zhang, X., Liu, L., and Gelb, M. H. (1995) Biochemistry 35, 11910-11918
  29. Goalstone, M. L., and Draznin, B. (1996) J. Biol. Chem. 271, 27585-27589[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.